SUPPLEMENTARY DATA

Alu RNA regulates the cellular pool of active ribosomes by targeted delivery of

SRP9/14 to 40S subunits

Elena Ivanova, Audrey Berger, Anne Scherrer, Elena Alkalaeva and Katharina Strub

Supplementary Data includes Supplementary Methods, Supplementary References and nine Supplementary Figures.

SUPPLEMENTARY METHODS

Plasmids

Vectors for expression of h9/14, h9/14A5, h9-3A/14 were described in (1,2). Plasmids encoding the eukaryotic translation initiation factors eIF1, 1A, 4A, 4B, 4G, 5, 5B and *Escherichia coli* Met-tRNA synthetase were described in (3). pGL3R-βglo, pGL3R-Bact, pGL3R-L1, pGL3R-HCV, pGL3R-EMCV, pGl3R-CrPV were the kind gift of Dr. Sergey Dmitriev (4). PCR fragments amplified from these constructs and containing the Firefly luciferase ORF fused to 5'-UTRs of β -globin, β -actin, LINE-1, HCV IRES or CrPV IRES under the control of SP6 promoter was inserted to pUC18 plasmid digested by HindIII and EcoRI to generate pUCgglo, pUCgact and pUCL1, and by PstI and EcoRI to generate pUCHCV and pUCCrPV. Vectors for in vivo expression of monocistronic mRNAs containing Firefly luciferase ORF fused to 5'-UTRs of β -globin, β -actin and LINE-1 were prepared by insertion of PCR fragment containing respective 5'-UTRs to pGL3R-EMCV digested by AfIII and Ncol to remove upstream Renilla luciferase ORF and EMCV IRES. Plasmid pCrPV-VHLM was constructed by insertion of T7 promoter, CrPV IRES nucleotides 6028 to 6216 followed by a short ORF encoding Val-His-Leu-Met tripeptide, UAA stop codon and 100 nt random sequence taken from β -glucuronidase (GUS) gene, into the pUC18 vector. Plasmids pscAluYb8, pscAluYf2, pscAluYj4 were obtained from the plasmids pscAlu/ α -feto and pSscAlu/LDL (1) using quick change protocol. pSAlu110 and pSAlu151 contained the Alu portion of 7SL RNA gene (nucleotides 1-74; 271-299 and 1-99; 251-299, respectively) with a closing loop GATT following position 74 or 99, preceded by the T7 promoter.

The pDLscAlu construct for scAluY^{NF1} RNA expression in cell lines was obtained by removing the neo^{Tet} reporter gene, Alu right arm and the internal A-rich linker from Alu-neo^{Tet} plasmid (5). The pDLscAluG25C construct was derived from pDLscAlu using the quick change protocol. Vector control plasmid pDL7enh was generated by digestion of pDLscAlu plasmid at Eagl/EcoRI sites to remove the scAluY^{NF1} RNA coding sequence, followed by treatment with DNA Polymerase I, Large (Klenow) Fragment (Promega, Madison, WI) and ligation with T4 DNA ligase (Promega). Constructs for *in vivo* expression of 4.5S RNA and 7SL RNA were obtained by digestion of pDLscAlu with Eagl and Spel and insertion of the PCR fragment amplified from pS4.5S and p7Sswt (1), respectively.

In vitro transcription

Run-off *in vitro* transcription reactions were performed as described in (6,7). For [³²P]-MVHL-stop mRNA synthesis [³²P]-UTP was added to the transcription reaction. Preprolactin and MVHL-stop mRNAs were synthesized with SP6 RNA polymerase from plasmids pSP-BP4 (8) and MVHL-stop (9) linearized with EcoRI and XhoI. Capped and uncapped RNAs encoding Firefly luciferase fused to various 5'-UTRs were synthesized with SP6 RNA polymerase from plasmids pUCβglo, pUCβact, pUCL1, pUCCHV and pUCCrPV linearized with EcoRI. HCV-NS' and CrPV-VHLM mRNAs were synthesized with T7 RNA polymerase from plasmids pXL.HCV(40-373).NS' (10) and pCrPV-VHLM linearized with EcoRI and SspI, respectively. The mRNAs were purified by LiCI precipitation, G50 sepharose chromatography, ethanol precipitation, and resuspended in water. Non-coding AluY^A, scAluY^A, scAluY^L, and 4.5S RNAs were synthesized with T7 RNA polymerase from plasmids pPAlu, pPscAlu/a feto, pSscAlu/LDL and pS4.5S (1) linearized with SspI, SpeI and

Dral, respectively. SA110, SA151 and SA86 RNAs were synthesized in the same way from plasmids pSAlu110, pSA151 and pSA86 linearized with Xbal. Non-coding RNAs were purified on a preparative denaturing polyacrylamide gel as described (11).

Purification of proteins, RNPs, ribosomal subunits

Expression and purification of recombinant translation initiation factors eIF1, 1A, 4A, 4B, 4G, 5B, 5 and *Escherichia coli* Met-tRNA synthetase and purification of eIF2, eIF3, eEF1H, eEF2, 40S and 60S ribosomal subunits was performed as described in (3). Expression and purification of the recombinant eIF4GI₇₃₈₋₁₁₁₆ was done as described in (12). Human recombinant SRP9 and SRP14 proteins and their mutated forms were obtained as described previously (2) with minor modifications in purification procedure. Lysates of SRP9- and SRP14-overexpressing BL21pLysS cells were combined and SRP9/14 was purified by heparin-sepharose affinity chromatography, the eluted protein was dialysed against 50 mM Hepes pH 7.5, 300 mM potassium acetate, 1 mM EDTA, 0.01% Nikkol, 10 mM DTT and further purified by ion-exchange chromatography on cation exchanger (MonoS 5/50 GL, GE Healthcare). Fractions containing SRP9/14 were pooled and dialysed against 20 mM

Alu RNPs were assembled in the buffer containing 20 mM HEPES, 500 mM potassium acetate, 5 mM magnesium acetate, 0.1% Nikkol and 4 mM DTT and purified on Superdex 200 column as described in (11). High salt concentration was used to ensure a 1:1 stoichiometry and to avoid nonspecific binding of an additional molecule(s) of SRP9/14 to Alu RNA. Resulting RNPs were then dialyzed against buffer (20 mM HEPES, 150 mM potassium acetate, 1.5 mM magnesium acetate,

0.01% Nikkol, 4 mM DTT and 10% glycerol). The concentrations of the RNPs were determined based on the optical absorption of the RNA at 260 nm and were confirmed electrophoretically by comparing the RNA and protein contents of the RNPs to equal amounts of RNA and protein alone. All RNPs were examined for RNA integrity by denaturing polyacrylamide gel electrophoresis and the formation of the stoichiometric complexes with h9/14 was confirmed by Western blot analysis using anti-h14 antibodies.

Aminoacylation of the tRNA

Total calf liver tRNA (Novagen) was purified by size-exclusion chromatography through Superdex 200 column (GE Healthcare) and aminoacylated with rabbit aminocyl tRNA synthases from RRL and a mix of 22 amino acids. tRNA^{Met} from *E. coli* (a kind gift of Dr. Vasily Haurilyuk) was aminoacylated with methionine or [³⁵S]-methionine using *E. coli* methionyl-tRNA synthetase. Aminoacylation reactions were performed according to the previously described protocol (3).

Toeprinting analysis of ribosomal complexes

Translation complexes were analyzed by toeprint assay using fluorescently labeled DNA oligonucleotides: 5' [6-carboxyfluorescein] (FAM)-GCATGTGCAGAGGACAGG 3' for MVHL-stop mRNA, 5' (FAM)-GGGATTTCTGATCTCGGCG 3' for HCV-NS' mRNA, 5' (FAM)-TTAATGCGTGGTC 3' for CrPV-VHLM mRNA.

Ribosome binding assay

Binding assays were performed in 30 μ l by combining 3 pmols of purified ribosomal subunits or 43S complex with 3 pmols of scAluY^A/SA110 RNP or h9/14 in the binding buffer containing 20 mM Tris-HCl pH 7.5, 150 mM potassium acetate, 1.5 mM

magnesium acetate, 2 mM DTT, 0.01% Nikkol. The mixtures were incubated for 10 min. at 37°C, adjusted to 100 μ l and centrifuged through 5-20% sucrose gradient containing 20 mM Tris-HCl pH 7.5, 100 mM potassium acetate, 5 mM magnesium acetate, 2 mM DTT at 60000 rpm for 2 hours at 4°C in a Beckman SW60 rotor. To reassemble 80S ribosomes from high-salt purified 40S and 60S the subunits were incubated in equimolar amounts for 10 min. at 37°C in buffer containing 20 mM Tris-HCl pH 7.5, 150 mM potassium acetate, 1.5 mM magnesium acetate, 4 mM DTT. Then equimolar amount of scAuY^A RNP or h9/14 was added and reaction was incubated for another 10 min. in the binding buffer before centrifugation through 10-30% sucrose gradients at 40000 rpm for 5 hours in a Beckmann SW41 rotor. Fractions were analyzed for the presence of h14 and S15 or L9 by Western blotting and for scAlu or SA110 RNA by Northern blotting.

Cell culture

HEK293T cells were cultivated in DMEM supplemented with 10% fetal bovine serum, 2mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin.

Polysome fractionation

HEK 293T cells were incubated 10 min. with 100 μ g/ml cycloheximide and lysed in 50 mM Tris-HCl (pH 7.5), 15 mM MgCl₂, 100 mM potassium acetate, 0.5% NP-40, 2 mM DTT, 100 μ g/ml cycloheximide, spun at 10000 x g for 5 min. and loaded on 7-50% linear sucrose gradients (50 mM Tris-HCl pH 7.5, 100 mM potassium acetate, 12 mM MgCl₂, 2 mM DTT) and centrifuged at 35000 rpm in a SW41 rotor for 3.5 hours. Following centrifugation gradients were displaced with 60% sucrose solution through a flow cell recording absorbance at 254 nM.

Nothern blot

Total cellular RNA was extracted using Tri-reagent (Sigma-Aldrich, St. Louis, MO), separated on 1% agarose-formaldehyde gel and transferred to Hybond-N membrane (GE Healthcare, Waukesha, WI). The following radiolabeled oligonucleotides were used for detection: 5' ATCGGGTGTCCGCACTAAG 3' for 7SL RNA, 5' TCACCATGTTAGCCAGGATGGT 3' for scAluY RNA, 5' GGGCATCACAGACCTGTT 3' for 18S rRNA, 5' TCCCGAGTAGCTGGGACTACAGG 3' SA110 RNA, 5' for GCCCAGGCTGGCCTCGAACTCGTG 3' for 4.5S RNA.

SUPPLEMENTARY REFERENCES

1. Bovia, F., Wolff, N., Ryser, S. and Strub, K. (1997) The SRP9/14 subunit of the human signal recognition particle binds to a variety of Alu-like RNAs and with higher affinity than its mouse homolog. *Nucleic Acids Res.*, **25**, 318-326.

2. Mary, C., Scherrer, A., Huck, L., Lakkaraju, A.K., Thomas, Y., Johnson, A.E. and Strub, K. (2010) Residues in SRP9/14 essential for elongation arrest activity of the signal recognition particle define a positively charged functional domain on one side of the protein. *RNA*, **16**, 969-979.

3. Pisarev, A.V., Unbehaun, A., Hellen, C.U. and Pestova, T.V. (2007) Assembly and analysis of eukaryotic translation initiation complexes. *Methods Enzymol.*, **430**, 147-177.

4. Andreev, D.E., Dmitriev, S.E., Terenin, I.M., Prassolov, V.S., Merrick, W.C. and Shatsky, I.N. (2009) Differential contribution of the m7G-cap to the 5' end-dependent translation initiation of mammalian mRNAs. *Nucleic Acids Res.*, **37**, 6135-6147.

5. Dewannieux, M., Esnault, C. and Heidmann, T. (2003) LINE-mediated retrotransposition of marked Alu sequences. *Nat. Genet.*, **35**, 41-48.

6. Gurevich, V.V., Pokrovskaya, I.D., Obukhova, T.A. and Zozulya, S.A. (1991) Preparative in vitro mRNA synthesis using SP6 and T7 RNA polymerases. *Anal. Biochem.*, **195**, 207-213.

7. Milligan, J.F. and Uhlenbeck, O.C. (1989) Synthesis of small RNAs using T7 RNA polymerase. *Methods Enzymol.*, **180**, 51-62.

8. Siegel, V. and Walter, P. (1988) Each of the activities of signal recognition particle (SRP) is contained within a distinct domain: analysis of biochemical mutants of SRP. *Cell*, **52**, 39-49.

9. Alkalaeva, E.Z., Pisarev, A.V., Frolova, L.Y., Kisselev, L.L. and Pestova, T.V. (2006) In vitro reconstitution of eukaryotic translation reveals cooperativity between release factors eRF1 and eRF3. *Cell*, **125**, 1125-1136.

10. Reynolds, J.E., Kaminski, A., Kettinen, H.J., Grace, K., Clarke, B.E., Carroll, A.R., Rowlands, D.J. and Jackson, R.J. (1995) Unique features of internal initiation of hepatitis C virus RNA translation. *EMBO J.*, **14**, 6010-6020.

11. Hasler, J. and Strub, K. (2006) Alu RNP and Alu RNA regulate translation initiation in vitro. *Nucleic Acids Res.*, **34**, 2374-2385.

12. Kolupaeva, V.G., de Breyne, S., Pestova, T.V. and Hellen, C.U. (2007) In vitro reconstitution and biochemical characterization of translation initiation by internal ribosomal entry. *Methods Enzymol.*, **430**, 409-439.



Fig. S1: Preparation of Alu RNPs

(A) Schematic representation of the Alu RNP purification procedure with a typical OD260 elution profile of a Superdex 200 column.

(**B**) Denaturing polyacrylamide gel electrophoresis of 150 ng of AluY^A RNP and scAluY^A RNP after proteinase K digestion. The concentration of RNPs was estimated by OD260 measurement. Same amounts of AluY^A RNA and scAluY^A RNA were loaded on the gel as a control of quantification.

(C) Immunoblotting of 50 fmols of AluY^A RNP and scAluY^A RNP with anti-h14 antibodies.

Fig. S1, Ivanova et al.



Fig. S2: Alu RNPs dose-dependently inhibit 48S complex formation and do not affect assembly of the 80S and pretermination complexes.

(A) and (B) Representative autoradiographs from experiments described in Figure 1B. Concentrations of RNPs and translation efficiencies of pPL mRNA are indicated below.

(C) Representative autoradiograph from experiments described in Figure 1C. RRL programmed with pPL mRNA was incubated 3 min. prior to addition of 0.5 μ M edeine. Alu RNPs were added after 1 min. incubation with edeine.

(**D**) Electropherograms of toeprint assays of the MVHL mRNA in the absence of 40S and initiation factors and upon the 48S assembly on it.



Fig. S3. Analysis of different scAlu Y RNPs and SA RNPs.

(A) Secondary structure model of the SA151 RNA. Dashed lines mark portions included in SA110 and SA86 RNAs.

(B) Representative autoradiographs from the experiments described in Figure 2A. Concentrations of RNPs and translation efficiencies of preprolactine mRNA in RRL are indicated below.

(**C**) Sequence alignment of Alu elements from the Y family and of the SA110 portion of the 7SL RNA gene (see also Table 1). Identical nucleotides are shown as dots.

(D) Representative autoradiographs from experiments described in Figure 2E. Translation efficiencies of pPL mRNA are indicated below.

(E) Denaturing polyacrylamide gel eletrophoresis of 150 ng of SA151, SA110, SA86, scAluY^L, scAluYa5, scAluYf2, scAluYj4 RNPs (left panel) and Western blot of 50 fmols of SA151, SA110, SA86, scAluYa5, scAluYf2, scAluYj4 RNPs (right panel) with anti-h14 antibodies.



Fig. S4. Analysis of Alu RNPs containing mutated h9/14.

(A) Denaturing polyacrylamide gel eletrophoresis after proteinase K digestion (left panel) and Western blot analysis with anti-h14 antibodies (right panel) of scAluY^A, scAluY^A 14A5, scAluY^A 9-3A RNPs.

(**B**) Representative autoradiographs from experiments described in Figure 2E. Translation efficiencies of pPL mRNA are indicated below.



Fig. S5. Alu RNPs inhibit cap-dependent and cap-independent translation in RRL.

(A) Representative autoradiographs from experiments described in Figure 4A. Translation efficiencies of mRNAs examined are indicated below.

(B) Toeprint analysis of the CrPV-VHLM mRNA in the absence and in the presence of 40S subunits. No toeprints were observed at the position of the 48S complex in the absence of 40S.

Fig. S5, Ivanova et al.

А



Fig. S6. Binding of h9/14 and scAlu Y^A RNP to 40S subunits.

Two-fold molar excess of h914 (**A**) or scAlu Y^A RNP (**B**) was incubated with 3 pmols of high-salt purified 40S for 10 min. at 37°C and fractionated on 5-20% sucrose gradients. 40S-containing fractions were determined by probing for S15.



Fig. S7. Representative autoradiographs from the experiments described in Figure 5C. Translation efficiencies of pPL mRNA are indicated below.

Fig. S7, Ivanova et al.



Fig. S8. Expression of Alu RNA affects translation in HEK 293T cells.

(A) Northern blot analysis of luciferase reporter mRNAs in HEK 293T cells expressing ncRNAs.

(B) Representative autoradiograph (left panel) and coomassie blue staining (right panel) following SDS-PAGE of lysates of HEK 293T cells transfected with pDLscAlu or empty vector (Ctrl). Cells were harvested 48 hours post transfection.

(C) Polysome profiles from HEK 293T cells in the absence of arsenite treatment (left panel) and cells incubated with 0.5μ M sodium arsenite for 30 min. and allowed to recover for another 60 min. Cell lysates were fractionated on 7-50% sucrose density gradient.

(**D**) Northern blot analysis of transiently transfected HEK 293T cells after arsenite treatment. Cells were treated with 500 μ M sodium arsenite for 30 min. at 48 hours post transfection and allowed to recover for the indicated times.

(E) Northern blot analysis of transiently transfected HEK 293T cells after VSV infection for 6 hours.

Fig. S8, Ivanova et al.

SRP14	(94-102)	L K K R D <mark>K K </mark> N K
DHX29	(353-361)	ЕЕКДКККЕР
elF3j	(217-226)	SKAKKKKG
elF5	(155-163)	KKEKEKKNR
elF5B	(313-321)	кккк <mark>р</mark> кккк
RPS5	(191-199)	K K K D E L E R V
RPS6	(164-172)	K E G <mark>K K </mark> P R T K
RPS8	(139-148)	KKRSKKIQK
RPS25	(4-13)	K D D K K K K D A
RPS27	(16-25)	K R K H K K K R L
ERj1p	(185-194)	R K K R E K K K K
NACb	(71-80)	R R K K K V V H R

Fig. S9. Basic oligopeptides are found in many ribosome ligands and ribosomal proteins.